Adjunctive therapy with inhaled nitric oxide for severe acute chest syndrome in patients with sickle cell disease

Wrigge, Hermann; Costa, Eduardo F.; Busch, Thilo

doi:10.1007/s00134-015-4084-7

Cited by 2 publications

(1 citation statement)

References 11 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may in theory, decrease pulmonary hypertension and sickling. 24 One clinical trial demonstrated no difference in mortality, rate of mechanical ventilation, Alveolar-arterial gradient or rate of transfusion. However, a post hoc analysis with larger sample size does show a significant benefit in hypoxemic ACS patients compared to placebo.…”

Section: Bronchodilatorsmentioning

confidence: 99%

Acute Chest Syndrome: A narrative review to guide inpatient management

Wang,

Das-Ireland

2022

AJHM

View full text Add to dashboard Cite

Introduction: Acute Chest Syndrome (ACS) is a leading complication of sickle cell disease (SCD) with significant morbidity and mortality. The current practice guidelines lack sufficient detail on the evidence behind our standard of practice. Materials and Methods: A comprehensive literature search was accomplished with PubMed with a particular focus on literatures published between 2015-2021 with the keywords ACS management, vaso-occlusive crisis, sickle cell, antibiotics, opioids, transfusion, fluid, steroids, bronchodilators, incentive spirometry, anticoagulation, oxygen, prevention, and SARS-CoV2. We included literatures both in the adult and pediatric population. Results/Discussion: ACS is defined as a new infiltrate in a chest radiograph involving at least one broncho-pulmonary segment in an individual with one additional clinical finding. There are multiple causes of ACS which include infections, pulmonary edema, pulmonary infection, hypoxemia and hypoventilation. The goal is to quickly diagnose and treat this condition to prevent irreversible lung damage and mortality. In this narrative review, we discuss why a balanced approach to fluid and pain management will provide better outcome for patients, and the evidence behind using antibiotics, steroids, bronchodilators, nitric oxide, incentive spirometry, as well as the current management of patients with concomitant ACS and SARS-CoV2. Conclusion:All patients admitted with ACS should be started on a third-generation cephalosporin and macrolide or a fourth-generation fluoroquinolone, incentive spirometry, thromboprophylaxis, oxygen and simple or exchange transfusion if needed, with a balanced approach to fluid resuscitation and pain control.

show abstract

Section: Bronchodilatorsmentioning

confidence: 99%